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1. Crystalline Solids and Pharmaceutical ingredients 
Active Pharmaceutical Ingredients (APIs) - agents responsible for the 
pharmacological properties of a drug - are often administered in solid state as, for instance, 
in tablets, capsules, granules or draggers. Solid forms of oral use are the most widely 
used.1-3 They are normally composed by one or more APIs as well as excipients. The 
molecules of the APIs are grouped into two large classes in the solid state. As the 
_____________________________________________‡‡_______________________________________________ 
Abstract. High-efficiency drugs and pharmaceutical formulations, produced in a 
sustainable way, and that present a favorable performance are widely required in public 
health. Among the pharmacokinetic properties of active pharmaceutical ingredients 
(APIs), the solubility is main variable since it regulate the availability in the biological 
target. Numerous formulations in the market and in the Brazilian National Health 
System (SUS) present serious drawbacks related to quality, manufacture and 
performance. In general, APIs are delivered in solid formulations and this characteristic 
represents a challenge for industry and academia since the therapeutic efficiency of an 
APIs is related to their crystalline structure, i.d structural multiplicity, polymorphism 
and composition. APIs may exist in different forms presenting different 
pharmacokinetic profiles. In addition, the characterization of the diversities of solid 
forms of an API, constitutes an innovative strategy to optimize pharmaceutical 
properties, providing opportunities for the creation of intellectual property and 
innovation for the country. In this work we will discuss several strategies related to the 
problem aiming to show the importance in the pharmaceutical area of solid state 
techniques like crystal engineering.  
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tridimensional structure, the solid state can be classified into crystalline when they present 
a structural organization or amorphous otherwise. In the pharmaceutical sciences, the 
crystalline solid (crystals) is a convenient and practical way for the formulation process 
and storage APIs, since crystals are thermodynamically more stable than amorphous. This 
fact guarantees that, in the production and development of medicines, the API has a 
reproducible way of delivery taking the drug to the right place and at the right time. In this 
way, the solid-state properties of an API influence from the manufacture procedure until its 
absorption into the system (Figure 1). 
 
Figure 1. A medicine administered in the form of tablets consists of a pharmaceutical solid form 
whose main component is the API molecule. The identity of the solid (tridimensional crystal 
Structure) is strongly related with the physicochemical properties and performance of a drug. 
As all crystalline solids, the APIs may be found in a large variety of different solid 
forms being able to aggregate into single component forms as well as in multicomponent 
ones. Over the past few decades, research aimed at developing solid modifications with 
specific properties has led to the design of different multicomponent systems which can be 
classified in different ways. Figure 2 shows one of these classification system. For 
amorphous solids, the same principles of classification are applied. Crystalline APIs may 
contain solvent molecules in the crystal structure, whose phases are now referred to 
solvates. The term hydrate is used for crystalline structures that contain water molecule(s) 
in their structure. On the other hand, the term salts is used for multicomponent solids 
resulting from the aggregation of different species by the formation of ionic units. 
Cocrystals, however, come from the aggregation of an API with other molecules (which 
may or not be also an API) in a single phase without the occurrence of charge transfers. In 
addition to these solid forms, it is still possible to form crystal lattices composed by ionic 
unit associates to neutral forms referred to salt-cocrystals or ionic cocrystals. It should also 
be considered that crystalline solids can exhibit polymorphic forms, containing the same 
chemical composition but presenting different internal structures, which arise from the 
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disparities in crystalline packaging resulting from the combination of different molecular 
conformations with the different possibilities of intermolecular interactions. Polymorphism 
is of fundamental importance in the pharmaceutical sciences. Bernstein et al. observed that 
at least 50% of APIs have at least some type of reported polymorphism.4 A similar level of 
occurrence is also observed for salts, crystals, solvates and hydrates.  
 
Figure 2 - Classification scheme of single and multicomponent solid forms of APIs (b) Vien 
Diagram of solid forms of APIs classification as Gelder et al.5  
An API must have adequate physicochemical properties to ensure optimal 
pharmacokinetic performance. Unfortunately, some APIs, even with highly desirable 
pharmacological properties, can never reach their maximum potential because their 
physical and chemical properties in the solid state often end up strongly conditioning their 
bioavailability. Among the properties that determine the action of drugs and that strongly 
influence bioavailability we can mention the solubility. On the other hand, soluble and 
permeable compounds are able to cross membranes more easily and to be absorbed so that 
they can exert their therapeutic action. The Biopharmaceutical Classification System 
(BSC) provided by the U.S. Food and Drug Administration (FDA) is a guide for predicting 
drug absorption. In this system, APIs are classified into four classes according to their 
solubility and intestinal permeability. APIs limited by solubility are grouped into classes II 
and IV. It is worth remembering that in order to prepare this classification, the solid form 
of the API in question is specifically considered. 
Different solid forms of the same pharmaceutical compound can have different 
chemical and physical properties. Thus, the development of new solid forms of an API has 
the potential to modify its dissolution, solubility and absorption. These variations are 
related to changes in its crystalline packaging due to the changes in the intermolecular 
interactions pattern. The coexistence of another component in the crystalline network alters 
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the system of intermolecular interactions, thus leading to modifications of the internal 
energy of interaction and, consequently, of enthalpy, which finally results in the 
occurrence of different physical-chemical properties. Often, the solubility of an API can be 
altered by using a more soluble multicomponent form, whether in the form of salts or 
cocrystals, for example. Historically, the formation of pharmaceutical salts is the main 
choice for overcoming solubility problems. APIs in the form of salts are usually more 
soluble than their neutral forms, so they are better absorbed. However, this technique is 
correlated to the existence of an ionizable group in the API molecule, which may not often 
be the case. 
In addition to modifying aqueous solubility, differences in solid crystalline forms 
also affect thermodynamic parameters, such as fluidity, compression, compaction, density, 
hardness, stability, etc. The selection of an appropriate solid form of an API for its 
pharmaceutical formulation also influences industrial parameters such as the 
manufacturability, processing, storage and shelf life of a drug. It is desirable that the API 
be stable and does not suffer modifications during the manufacturing process, preserving 
its structure until its administration. Thus, unexpected solid-solid transformations during 
their processing may result in the failure of quality controls of the final product. As one of 
the main examples, we can mention the occurrence of unknown polymorphic phases in the 
manufacture processes that changed the way in which the pharmaceutical industry looks at 
the solid forms. The antiretroviral drug ritonavir exemplifies this case (Figure 3). This API 
had solubility problems due to the formation of a polymorphic form of unknown structure 
during the formulation of the drug.4 Once the relationship between the different 
polymorphs was stablish, an effective way to solve the pharmaceutical problem was obtain 
but until that the product was taken off the shelves. The new formulation take its place 
more than a year later generating billions of dollars in losses.  
Similarly, the exposure of the pharmaceutical product to high humidity during its 
storage could lead to the transformation of APIs in their hydrated phases.6 For example, 
Carbamazepine, a drug widely used in the treatment of certain types of seizures and 
epilepsies, has two solid forms, one stable and one metastable (Figure 3). The latter can 
suffer a solid-solid phase transformation to its dihydrated phase when exposed to water 
vapor at temperatures above 37ºC.7-8 For these reasons, the knowledge of the melting point 
as well as the dehydration temperature (for hydrates) of a phase is an invaluable tool in 
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determining its physical stability for a given manufacturing route, as many processes, such 
as grinding and compaction, could lead to an increase in the temperature of the API. Thus, 
hygroscopicity and hydration/dehydration processes are properties that could be 
successfully controlled and even modulated by changing the solid form of the 
pharmaceutical ingredient to be used in the final formulation. Given this context, in the last 
decades, regulatory agencies have intensified the characterization and the standardization 
in the production of pharmaceutical solids.  
 
Figure 3: (a) Polymorphic forms of ritonavir involved in the API manufacturing process. 
 (b) Occurrence of the dihydrated form of carbamazepine in API dispersions.  
Considering the structure/property relationship established by the variability of 
solid APIs, the development of appropriate techniques for the correct selection of the form 
to be used in the formulation has been strongly consolidated in the pharmaceutical 
industry. There are a significant number of cases that demonstrate that the identification 
and characterization of solid multicomponent or polymorphic forms of APIs in the early 
stages of drug development is an interesting and attractive opportunity for the 
improvement of the formulations as well as the best path to avoid intellectual property. 
Problems. As examples, we can cite a work involving the synthesis of salts and crystals of 
the antifungal miconazole.9 The maleate and nitrate salts and the fumaric and succinic 
acids cocrystals showed a significant increase in the solubility and in the percentage of 
drug dissolved in the intrinsic dissolution tests in relation to the free base. Another 
example reported in the literature involve the anti-diabetic gliclazide. Chadha10 and 
collaborators showed that the maximum plasma concentration (Cmax) of two co-crystals of 
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this API with succinic and malic acids, was increased about 1.5 times in comparison with 
the Cmax of Gliclazide. In this context, the selection of an appropriate multicomponent form 
provides the opportunity to modify its pharmacokinetic and pharmaceutical characteristics. 
Even when the variation of physicochemical properties in different solid forms is 
well known, it is not possible to predict a priori which properties could be modified or how 
they could be modified. We thus have that the number of crystalline modifications depends 
on structural and kinetic factors as well as “on the time and the financial investment in the 
search for these new crystalline arrangements”.2,4,8 The process of selecting an appropriate 
solid form of APIs is not a trivial exercise, as numerous different solid forms are possible 
for a given API. In fact, understanding, controlling and optimizing the main factors in the 
formation of multicomponent forms is a fundamental task and often difficult one to 
achieve. In the search for optimal solid forms of APIs, a scientific approach is to alter and 
control solid state properties without changing the pharmacophoric unit using, for example, 
the Crystal Engineering (CE) methods. 
CE is used in this perspective for the generation of new multicomponent forms 
based on the principles of supramolecular chemistry and molecular recognition. It is one of 
the main areas of contemporary solid-state chemistry and results from an intimate 
relationship between supramolecular chemistry and crystallography. The investigation of 
the diversity of solid forms via CE has been shown to be innovative in both basic research 
and industry.4 Therefore, the knowledge of which characteristics of an API to optimize, 
using the CE strategy, is of great use for the pharmaceutical industry. This scenario has 
provided opportunities for the development of new drugs and for the optimization of 
pharmaceutical formulations, since each solid form of an API can exhibit unique physico-
chemical properties, therefore being considered as New Chemical Entities (NECs) and, as 
such, candidates for new drugs. 
The pharmaceutical industry is currently experiencing a continuing crisis due to 
rising R&D costs, a decline in the number of products marketed and expiration of 
blockbuster drug patents (those whose sales provide annual revenues of more than Us$ 1 
billion in the global market). Drug research and development is a long, expensive and 
arduous process, which is generally associated with a high risk and low success rate. Less 
than 1% APIs are successfully developed and appear on the market. Difficulties in the 
development of new pharmaceutical products have stimulated research in the field of 
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multicomponent pharmaceutical solids, since these can be designed beforehand and can be 
developed to have the desired properties such as better solubility, greater stability and in 
some cases even better pharmacological performance. Since the properties of the materials 
dependent on their solid-state structure, it is evident that solid-state modifications can be 
designed to decrease and even suppress the undesirable pharmacokinetic and 
pharmacodynamic properties of the APIs. 
From an economic perspective, the research on multicomponent phases contributes 
to the lowering the production cost of APIs, since new patents with reduced production 
prices can be generated. As each form is unique, and its design and development are not 
usually “obvious”, they characterize a technological innovation, so they can be protected 
and, as such, they may have its own patentable intellectual property. The emergence of 
new forms of APIs contributes to the expansion of intellectual properties with new patents 
of modified forms. The identification of new phases of APIs with promising improved 
properties, may led to the rapid development of a large number of candidates and possible 
formulations - ensuring that the time from the discovery of patentable NCE until its exit to 
the market may be much shorter since they can be prove to be bioequivalent to the 
reference API. In this way, the first phases of clinical trials do not need to be repeated, thus 
greatly reducing development costs and greatly shortening the time to market. 
This context is of primary importance for drugs listed in classes II and IV of the 
Biopharmaceutical Classification System (BCS) that are already on the market and have 
limited action due its low solubility. Especially for those used to treat prevalent diseases in 
Brazil such as depression, systemic arterial hypertension, diabetes and infections in 
general. These diseases are of great relevance, incidence and have a huge social impact. 11 
According to the World Health Organization, these constitute challenges for public health12 
due to aspects inherent to treatment and diagnoses. These are the main prospective causes 
of disability in the world over the next 30 years12-13. As they are diseases that require long 
and continuous treatment, it is important to develop safer, more efficient and cheaper 
drugs. For APIs in these classes, finding an ideal solid form is important. Additionally, this 
area of research supports the development of new technologies for the discovery of new 
APIs and the expansion of intellectual property (new patents). The search for new 
crystalline forms, as well as the characterization and standardization of new analytical 
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methods for the analysis/control of the drug production line are challenges for the 
pharmaceutical industry. 
2. Conclusions and perspectives 
Drug innovation strategies, aiming to increase efficiency and to reduce production 
costs, constitute an important demand from the Brazilian National Health System (SUS). 
The production of medicines, from their formulation to their commercialization, presents 
important costs that can be reduced using CE techniques. In addition, numerous 
formulations available on the market and in the SUS have drawbacks related to quality 
control, manufacturing problems and difficulties in product performance that can also be 
address using CE techniques. In a social context, innovation in this area consists of the 
generation/production of new pharmaceutical products effective in combating a disease, 
which may led to reduction in production costs and get improvement to health of the 
society. Medicines represent the main pathological assistance interventions. Given the 
rising costs of discovering new drugs, it is clear that investment and efforts in innovative 
strategies can be focused on studies of new pharmaceutical formulations of already known 
APIs. There are several strategies to achieve that goal, however, Crystal Engineering (EC) 
has emerged as a cost-effective very promising process for APIs optimization. CE have as 
a main objective the search for functional products with optimized properties, the so call 
Taylor-Made materials. It can also be associated to the Green Chemistry principles through 
the application of mechanochemistry process, thus reducing the environmental impacts of 
the exhausting drug discovery process. This area of research is in the interface of 
supramolecular chemistry and crystallography. It represent an important technical-
scientific issue for Brazil, since its products may be transform in NCEs that could be 
plausible to be patented. Unfortunately, Brazil does not have neither the time nor money 
necessary to develop new drugs from scratch. We need medicines now and at reasonable 
costs. Is at this point that CE applied to pharmaceutical solids will be of great importance 
in the coming years as it has been already for several years in others developing countries 
like India and China. Those countries are today much better prepared to face these 
pandemic times that we are going through. This innovation represents the possibility to 
obtain incremental patents as well as other registrations. Such aspects are vital for public 
health since innovation can provide value-added drugs at more reasonable costs. 
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